Prolactin-secreting tumors: What's new?

Expert Review of Anticancer Therapy

Volumn 6, Issue 9 SUPPL., 2006, Pages

  Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bromocriptine; Cabergoline; Pituitary tumor; Prolactin; Prolactinoma

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CLOMIPRAMINE; COCAINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; FLUOXETINE; HALOPERIDOL; METHYLDOPA; METOCLOPRAMIDE; MOLINDONE; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PERGOLIDE MESILATE; PHENOTHIAZINE; PROLACTIN; QUINAGOLIDE; RESERPINE; RISPERIDONE; THYROTROPIN; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

ACROMEGALY; ANAMNESIS; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL MALFORMATION; CUSHING DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECTOPIC PREGNANCY; EMPTY SELLA SYNDROME; EXPERIENCE; FEMALE INFERTILITY; FOLLOW UP; HEART MUSCLE FIBROSIS; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; HYPOPHYSITIS; HYPOTHALAMUS DISEASE; INDIVIDUALIZATION; MEDICAL DECISION MAKING; MULTIPLE PREGNANCY; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; OVULATION; PATHOGENESIS; PATIENT CARE; PATIENT MONITORING; PHYSICAL EXAMINATION; PREGNANCY; PREGNANCY TEST; PROLACTIN RELEASE; PROLACTINOMA; PSYCHOSIS; REPRODUCTION; REVIEW; SEXUAL DYSFUNCTION; SPONTANEOUS ABORTION; TRANSSPHENOIDAL SURGERY; TREATMENT INDICATION; TROPHOBLASTIC DISEASE; TUMOR VOLUME;

ANIMALS; DOPAMINE AGONISTS; FEMALE; HORMONE ANTAGONISTS; HUMANS; HYPERPROLACTINEMIA; PITUITARY NEOPLASMS; PREGNANCY; PROLACTIN; PROLACTINOMA;

EID: 33750081748     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.9.S29     Document Type: Review

References (69)

1. Molitch ME. Medical management of prolactinomas. Pituitary 5, 55-65 (2002).
2. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin. Proc. 80, 1050-1057 (2005).
3. Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am. J. Kidney Dis. 6, 245-249 (1985).
4. Honbo KS, Herle AJV, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. Am. J. Med. 64, 782-787 (1978).
5. Stryker TD, Molitch ME. Reversible hyperthyrotropinemia, hyperthyroxinemia and hyperprolactinemia due to adrenal insufficiency. Am. J. Med. 79, 271-276 (1985).
6. Boyd AE III, Spare S, Bower B et al. Neurogenic galactorrhea-amenorrhea. J. Clin. Endocrinol. Metab. 47, 1374-1377 (1978).
7. Molitch ME, Reichlin S. Hypothalamic hyperprolactinemia: neuroendocrine regulation of prolactin secretion in patients with lesions of the hypothalamus and pituitary stalk. In: Prolactin. Basic and Clinical Correlates. MacLeod RM, Thorner MO, Scapagnini U (Eds.), Liviana Press, Padova, Italy, 709-719 (1985).
8. Bevan JS, Burke CW, Esiri MM et al. Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. Am. J. Med. 82, 29-32 (1987).
9. St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin. Endocrinol. 44, 305-309 (1996).
10. Barkan A, Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the 'high-dose hook effect': case report. Neurosurgery 9, 13-15 (1998).
11. Martin TL, Kim M, Malarkey WB. The natural history of idiopathic hyperprolactinemia. J. Clin. Endocrinol. Metab. 60, 855-858 (1985).
12. Naidich MJ, Russell EJ. Current approaches to imaging of the sellar region and pituitary. Endocrinol. Metab. Clin. N. Am. 28, 45-79 (1999).
13. Molitch ME. Pituitary incidentalomas. Endocrinol. Metab. Clin. N. Am. 26, 725-740 (1997).
14. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485-534 (2006).
15. Tsang RW, Brierley JD, Panzarella T et al. Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother. Oncol. 41, 45-53 (1996).
16. Sheehan JP, Niranjan A, Sheehan JM et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical armamentarium. J. Neurosurg. 102, 678-691 (2005).
17. Feigl GC, Bonelli CM, Berghold A, Mokry M. Effects of γ knife radiosurgery of pituitary adenomas on pituitary function. J. Neurosurg. 97, 415-421 (2002).
18. Schran HR, Bhuta SI, Schwarz HJ et al. The pharmacokinetics of bromocriptine in man. In: Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects. Goldstein M, Calne D, Lieberman A, Thorner M (Eds). Raven Press, NY, USA, 125-189 (1980).
19. Lloyd HM, Jacobi JM, Willgoss DA. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine. Clin. Endocrinol. 43, 79-85 (1975).
20. Bevan JS, Webster J, Burke CW et al. Dopamine agonist and pituitary tumor shrinkage. Endocrine Rev. 13, 220-240 (1992).
21. Thorner MO, Perryman RL, Rogol AD et al. Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J. Clin. Endocrinol. Metab. 53, 480-483 (1981).
22. Pullan PT, Carroll WM, Chakera TMH et al. Management of extra-sellar pituitary tumours with bromocriptine: comparison of prolactin secreting and non-functioning tumours using half-field visual evoked potentials and computerised tomography. Aust. NZ J. Med. 15, 203-208 (1985).
23. Fahlbusch R, Buchfelder M, Schrell U. Short-term preoperative treatment of macroprolactinomas by dopamine agonists. J. Neurosurg. 67, 807-815 (1987)
24. Warfield A, Finkel DM, Schatz NJ et al. Bromocriptine treatment of prolactin- secreting pituitary adenomas may restore pituitary function. Ann. Intern. Med. 101, 783-785 (1984).
25. Passos VQ, Souza JJS, Musolina NRC et al. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J. Clin. Endocrinol. Metab. 87, 3578-3582 (2002).
26. Jasonni VM, Raffelli R, de March A et al. Vaginal bromocriptine in hyperprolactinemic patients and puerperal women. Acta Obstet. Gynecol. Scand. 70, 493-495 (1991).
27. Turner TH, Cookson JC, Wass JAH et al. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br. Med. J. 289, 1101-1103 (1984).
28. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary 8, 43-52 (2005).
29. Andreotti AC, Pianezzola E, Persiani S et al. Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin- lowering drug after administration of increasing oral doses [0.5, 1.0, and 1.5 milligrams] in healthy male volunteers. J. Clin. Endocrinol. Metab. 80, 841-845 (1995).
30. Webster J, Piscitelli G, Polli A et al. for the Cabergoline Comparative Study Group. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. 331, 904-909 (1994).
31. Biller BMK, Molitch ME, Vance ML et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J. Clin. Endocrinol. Metab. 81, 2338-2343 (1996).
32. Colao A, DiSarno A, Landi ML et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J. Clin. Endocrinol. Metab. 82, 3574-3579 (1997).
33. Verhelst J, Abs R, Maiter D et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab. 84, 2518-2522 (1999).
34. Colao A, DiSarno A, Landi ML et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective studying 110 patients. J. Clin. Endocrinol. Metab. 85, 2247-2252 (2000).
35. Motta T, Colombo N, De Vincentis S et al. Vaginal cabergoline in the treatmenet of hyperprolactinemic patients intolerant to oral dopaminergics. Fertil. Steril. 65, 440-442 (1996].
36. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N. Engl. J. Med. 349, 2023-2033 (2003)
37. Gillam MP, Middler S, Freed DJ, Molitch ME. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinomas. J. Clin. Endocrinol. Metab. 87, 4447-4451 (2002).
38. Freda PU, Andreadis CI, Khandj AG et al. Long-term treatment of prolactin- secreting macroadenomas with pergolide. J. Clin. Endocrinol. Metab. 85, 8-13 (2000).
39. Orrego JJ, Chandler WF, Barkan AL. Pergolide as primary therapy for macroprolactinomas. Pituitary 3, 251-256 (2000).
40. Horvath J, Fross RD, Kleiner-Fisman G et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov. Disord. 19, 656-662 (2004).
41. Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N. Engl. J. Med. 353, 1976-1977 (2005).
42. Bhatt MH, Keenan SP, Fleetham JA, Caine DB. Pleuropulmonary disease associated with dopamine agonist therapy. Ann. Neurol. 30, 613-616 (1991).
43. Corenblum B, Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil. Steril. 59, 671-673 (1993).
44. Testa G, Vegetti W, Motta T et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 58, 69-73 (1998).
45. Scheithauer BW, Sano T, Kovacs K et al. The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin. Proc. 65, 461-474 (1990).
46. Elster AD, Sanders TG, Vines FS et al. Size and shape of the pituitary gland during pregnancy and post partum: measurement with MRI imaging. Radiology 181, 531-535 (1991).
47. Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin. Wochenschr. 65, 823-827 (1987).
48. Krupp P, Monka C, Richter K. The safety aspects of infertility treatments. Program of the Second World Congress of Gynecology and Obstetrics, Rio de Janeiro, October 1988.
49. Raymond JP, Goldstein E, Konopka P et al. Follow-up of children born of bromocriptine-treated mothers. Hormone Res. 22, 239-246. (1985)
50. Konopka P, Raymond JP, Merceron RE et al. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am. J. Obstet. Gynecol. 146, 935-938 (1983).
51. Canales ES, García IC, Ruíz JE et al. Bromocriptine as prophylactic therapy in prolactinoma during pregnancy. Fertil. Steril. 36, 524-526 (1981).
52. Ruiz-Velasco V, Tolis G. Pregnancy in hyperprolactinemic women. Fertil. Steril. 41, 793-805 (1984).
53. Robert E, Musatti L, Piscitelli G et al. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod. Toxicol. 10, 333-337 (1996).
54. Pharmacia & Upjohn, Inc.: Data on File, October (1997).
55. Musolino NRC, Bronstein MD. Prolactinomas and pregnancy. In: Pituitary Tumors and Pregnancy. Bronstein MD (Ed.). Kluwer Academic Publishers, MA, USA 91-108 (2001).
56. Ricci E, Parazzini F, Motta T et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod. Toxicol. 16, 791-793 (2002).
57. Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Fertil. Steril. 31, 363-372 (1979).
58. Molitch ME. Pregnancy and the hyperprolactinemic woman. N. Engl. J. Med. 312, 1365-1370 (1985).
59. Kupersmith MJ, Rosenberg C, Kleinberg D. Visual loss in pregnant women with pituitary adenomas. Ann. Intern. Med. 121, 473-477 (1994).
60. Rossi A-M, Vilska S, Heinonen PK. Outcome of pregnancies in women with treated or untreated hyperprolactinemia. Eur. J. Obstet. Gynecol. Reprod. Biol. 63, 143-146 (1995).
61. Divers WA Jr, Yen SSC. Prolactin-producing microadenomas in pregnancy. Obstet. Gynecol. 61, 425-429 (1983).
62. Brodsky JB, Cohen EN, Brown BW Jr et al. Surgery during pregnancy and fetal outcome. Am. J. Obstet. Gynecol. 138, 1165-1167 (1980).
63. Murray RD, Kim K, Ren SG et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J. Clin. Endocrinol. Metab. 89, 3027-3032 (2004).
64. Saveanu A, Lavaque E, Gunz G et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J. Clin. Endocrinol. Metab. 87, 5545-5552 (2002).
65. Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol. Cell Endocrinol. 239, 27-36 (2005).
66. Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr. Rev. 26, 400-422 (2005).
67. Lee EJ, Jameson JL. Gene therapy of pituitary disease. J. Endocrinol. 185, 353-362 (2005).
68. Heaney AP, Melmed S. Molecular targets in pituitary tumours. Nat. Rev. Cancer 4, 285-295 (2004).
69. Molitch ME: Pathologic hyperprolactinemia. Endocrinol. Metab. Clin. North Am. 21, 877 (1992).